Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

Osteogenesis Imperfecta Clinical Trial

Official title:

Multicenter Study to Evaluate Safety of Fresolimumab in Adults With Moderate-to-severe Osteogenesis Imperfecta

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03064074
• Other study ID #: H37912
• Status: Completed
• Phase: Phase 1
• Start date: November 15, 2017
• Est. completion date: July 4, 2022

Study information

• Verified date: July 2022
• Source: Baylor College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. OI can range from very severe to very mild. The current standard-of-care for severe types of OI involves the use of IV medications (bisphosphonates) and surgery to put rods in bones to strengthen them. These therapies, although often life-saving, are new and very little is known about their long-term effects on bone and other body systems. Transforming growth factor beta (TGF-β) is a protein important in bone formation. Fresolimumab is an antibody that can silence TGF-β . In studies with mice with OI, it has been shown that silencing TGF-β can lead to higher bone mass, quality and strength. The purpose of this study is to determine if fresolimumab is safe in the treatment of OI.

Description:

Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. OI can range from very severe to very mild. Individuals with the most severe type of OI may die at birth. People with severe OI who survive may have bowed arms and legs, very short stature and be unable to walk. People with the mildest form of OI may only break bones occasionally and have normal height and lifespan. Breaks can occur in any bone, but are most common in the arms and legs. The current standard-of-care for severe types of OI involves the use of IV medications (bisphosphonates) and surgery to put rods in bones to strengthen them. These therapies, although often life-saving, are new and very little is known about their long-term effects on bone and other body systems. TGF-β is a protein important in bone formation. Studies have shown that increased TGF-β activity leads to lower bone mass and strength and increased fractures. Fresolimumab is an antibody that can silence TGF-β . In studies with mice with OI, it has been shown that silencing TGF-β can lead to higher bone mass, quality and strength.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: July 4, 2022
• Est. primary completion date: July 4, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Willing and able to provide signed informed consent.

2. Are 18 years or older

3. Have a diagnosis of moderate-to-severe OI based on various clinical features

4. Have genetic mutations that include glycine substitution in COL1A1 or COL1A2, or pathogenic variants in CRTAP, PPIB, or LEPRE1 (if genetic information is unavailable at screening, this may be assessed at screening visit on a clinical or research basis).

5. Females of child-bearing potential must have a negative urine pregnancy test, agree to and have the ability to use acceptable birth control method for entire duration of the study.

6. For Males enrolled in the study, partners must agree to use an acceptable form of birth control for the entire duration of the study.

Exclusion Criteria:

1. Fracture less than 3 months prior to the screening visit.

2. Rodding or instruments that prevents reliable bone mineral density (BMD) assessment.

3. Have a known unhealed fracture involving a long bone.

4. Do not meet laboratory safety requirements such as: Vitamin D < 15 ng/dL Serum albumin-corrected calcium levels below 8 mg/dL, Hemoglobin < 10 g/dL, Platelet count < 75,000mm3;, Prothrombin time/(PT/INR) international normalized ratio > 1.5 times Upper Limit of Normal (ULN), Clinical or laboratory abnormality of Grade III or higher as assessed by CTCAE v4.0 which in the view of investigator would compromise safety.

5. Have an EKG with QTc of > 450 ms

6. Have a known allergy to fresolimumab.

7. Have current clinically significant infection.

8. Have a personal history of basal cell carcinoma, squamous cell carcinoma or keratoacanthomas, a personal history of cancer, recent or remote.

9. Have evidence of untreated cavities or planned invasive dental work during the study period.

10. Have had organ transplantation.

11. Have known or suspected valvular heart disease.

12. Plan to have skeletal surgery in the study period.

13. Have had osteotomy 5 months prior to the screening visit.

14. Being treated with zoledronic acid or pamidronate less than 12 months of screening OR oral bisphosphonates less than 6 months of screening OR teriparatide less than one year of screening.

15. Being treated with systemic glucocorticoids

16. Have autoimmune diseases being treated with glucocorticoids or other biologic agents.

17. Enrolled in another clinical trial and receiving treatment with another investigational agent

18. Pregnant or planning to get pregnant during the study period.

19. Nursing mothers.

Related Conditions & MeSH terms

• Osteogenesis Imperfecta

Intervention

Drug:
• Fresolimumab
The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.

Locations

Country	Name	City	State
United States	Baylor College of Medicine	Houston	Texas
United States	Oregon Health Science University	Portland	Oregon

Sponsors (3)

Lead Sponsor	Collaborator
Baylor College of Medicine	Genzyme, a Sanofi Company, Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Safety of single and repeat doses of fresolimumab will be assessed in adult patients with moderate to severe osteogenesis imperfecta	6 months for single dose study and 12 months for repeat dose study
Secondary	Percentage change in type 1 procollagen, N-terminal or P1NP, Osteocalcin or Ocn, and C-terminal telopeptide or CTX	Markers of bone turnover in blood will be assessed	6 months in single dose study and 12 months in repeat dose study
Secondary	Percent change in the areal BMD at the lumbar spine and hip	Areal bone mineral density (aBMD) at the hip or the lumbar spine as measured by DXA Scan	6 months in single dose study and 12 months in repeat dose study
Secondary	Difference in score of numeric rating scale for pain	The difference between baseline values and at month 12 will be assessed in the repeat dose study only	12 months
Secondary	Change in ml in FEV1	The change in absolute volumes of FEV1 will be assessed between baseline and 12 months in the repeat dose study only	12 months
Secondary	Change in ml in FVC	The change in absolute volumes of FVC will be assessed between baseline and 12 months in the repeat dose study only	12 months
Secondary	Percent change in volumetric bone mineral density at the radius	pQCT of forearm will be performed to assess the change in volumetric bone mineral density between baseline and 12 months in the repeat dose study only.	12 months
Secondary	Number of meters walked in 6 minutes	Standard 6 minute walk test will be performed to assess the difference between baseline and 12 months in the repeat dose study only	12 months